This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The Wall Street Journal, 5/20/94, p. R16.
SciClone Pharmaceuticals, Form 10-K, 3/30/94, pp. 14–15.
Business Week, 6/22/92, p. 108.
Business Week, 6/21/93, p. 144.
Business Week, 7/12/93, p. 136.
The New York Times, 4/29/94, p. C3.
The Los Angeles Times, 5/16/94, pp. D1,D6.
Hepatology, 1991, 14: 567–569.
Sturza's Medical Investment Letter, 6/1/93, pp. 1,4,6.
The Wall Street Journal, 3/19/93, p.C1.
SciClone Pharmaceuticals, CDA/ Spectrum 13F Institutional Ownership as of 12/31/93, Compact Disclosure D/SEC, May 1994, CD-ROM.
Medical Technology Stock Letter, 2/11/93, pp. 1, 3–4.
Money, June 1994, p. 69.
Bio/Technology, June 1993, 11: 664–665.
SciClone Pharmaceuticals, Form 10–Q, 5/12/94, p. 12.
Journal of Business Ethics, February 1994, 13: 111–123.
The New York Times, 5/25/94, p. C16.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rothenberg, L. Is corporate and analyst hype unethical?. Nat Biotechnol 12, 763–765 (1994). https://doi.org/10.1038/nbt0894-763
Issue Date:
DOI: https://doi.org/10.1038/nbt0894-763